FACS monitoring of lymphocyte-subsets in patients with discoid and subacute-cutaneous lupus erythematosus receiving low-dose methotrexate

Scandinavian Journal of Rheumatology

Volumn 31, Issue 4, 2002, Pages 216-220

  Boehm, Ingrid ^a   Wenzel, Jörg ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

B cells; CD3+CD4+ cells; CD3+CD8+ cells; Immunomodulation; Leukocytes; Lupus erythematosus; Lymphocytes; Methotrexate; Monocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; METHOTREXATE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BASAL CELL; CLINICAL ARTICLE; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; PRIORITY JOURNAL; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS;

ADULT; AGED; CD4-CD8 RATIO; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; LYMPHOCYTE SUBSETS; MALE; METHOTREXATE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0036354826     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097402320318404     Document Type: Article

References (18)

1. Methotrexate for the treatment of discoid lupus erythematosus
2. Discoid lupus erythematosus: Successful treatment with oral methotrexate
3. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate
4. Methotrexate for steroid-resistant systemic lupus erythematosus
5. Low-dose methotrexate: An immunomodifying therapeutic strategy for dermatologic diseases
6. Discoid and subacute cutaneous lupus erythematosus: Detection of differences in peripheral lymphocyte numbers
7. Presence of antinuclear antibodies in patients with lupus erythematosus is correlated with diminished T-helper cells
8. Fluorescence-activated cell sorter analysis in patients with cutaneous lupus erythematosus
9. Management of cutaneous lupus erythematosus with low-dose methotrexate: Indication for modulation of inflammatory mechanisms
10. Lack of immunosuppresive effect of low-dose oral methotrexate on lymphocytes in rheumatoid arthritis
11. The effects of methotrexate on the production and activity of interleukin-1
12. Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin 1β to the interleukin 1 receptor on target cells
13. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation
14. Mechanisms of action of methotrexate
15. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes
16. Suppression of B cell function by methotrexate and trimetrexate. Evidence of inhibition of purine biosynthesis as well as a major mechanism of action
17. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis?
18. Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis